KyungDong Pharm home
Prescription Medicines

Bonseron Tab. 150mg

Product Category
Osteoporosis treatment taken once a month
Active Ingredients
Sodium risedronate
Appearance
Light blue, oval, film-coated tablets
Reimbursement Code
648103450
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Sodium risedronate 2.5 hydrate (USP) ---- 172.1mg (150mg as sodium risedronate)
- Additives (tar color aluminum lake): Blue No. 2, Yellow No. 5
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry II blue (85F60751), crospovidone, hydroxypropyl cellulose

2. Effectiveness
Treatment and prevention of osteoporosis in postmenopausal women

3. Dosage and dosage
1. Adults: Sodium risedronate, 150 mg orally once a month.
2. Elderly: There is no need to adjust the dose in elderly people (over 60 years old) because the bioavailability and pharmacodynamics of this drug are similar to those in young people.
3. Children: Safety and effectiveness in children under 18 years of age have not been established.
4. Patients with renal impairment: There is no need to adjust the dose in patients with a creatinine clearance rate of more than 30 mL/min. It is contraindicated in patients with severe renal impairment whose creatinine clearance is less than 30 mL/min.

○ Since food interferes with the absorption of this medicine, take it at least 30 minutes before consuming food or drinks other than water for the first time during the day to ensure sufficient absorption.
To make it easier for this medication to reach the stomach and reduce the possibility of esophageal irritation, take this medication in an upright position with a sufficient amount of pure water (170 to 230 mL). Taking this drug with other beverages, including mineral water, may decrease the absorption of this drug. This medication should not be chewed or sucked due to the potential for ulceration of the oropharynx. And patients should not lie down for at least 30 minutes after taking the drug.

○ If the patient forgets to take the medicine on the prescribed day, take it as follows.
- If there are more than 7 days left until the next dose, remember to take 1 tablet of this medicine the next morning. The next dose should be taken on the previously scheduled dose date. At this time, you should not take more than 1 tablet of this medicine within 7 days.
- If there are less than 7 days left before the next dose, wait until the previously scheduled dose date and then take 1 tablet of this medicine.

4. Precautions for use
1. Warning
This drug, like other oral bisphosphonate preparations, may cause local irritation to the upper gastrointestinal mucosa. Because it has the potential to irritate the mucous membrane and worsen the underlying disease, caution should be exercised when administering it to patients with upper gastrointestinal diseases such as Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers.
In patients receiving oral bisphosphonates, esophageal adverse reactions such as esophagitis, esophageal ulcer, and esophageal erosion, along with bleeding, have been reported, and in rare cases, esophageal obstruction or perforation has been reported. In some patients, symptoms were severe and required hospitalization. Therefore, doctors should pay attention to all signs and symptoms that indicate an esophageal reaction, and instruct patients to stop taking the drug and consult a doctor if they experience symptoms such as dysphagia, dysphagia or retrosternal pain, or the development or worsening of heartburn.
The risk of serious esophageal adverse reactions is much greater in patients who lie down after taking this drug, do not take this drug with a sufficient amount of water (170 to 230 mL), or continue to take this drug after symptoms of esophageal irritation appear. Therefore, it is very important to explain and understand the Dosage and Administration to the patient (refer to the Dosage and Administration section). Treatment of this drug for patients who are unable to follow the prescribed dosage due to mental impairment should be conducted under appropriate supervision.
In post-marketing surveillance in foreign countries, cases of gastric ulcers and duodenal ulcers accompanied by some serious complications have been reported when administering oral bisphosphonates. This increased risk was not confirmed in controlled clinical trials.

2. Do not administer to the following patients.
1) Patients with esophageal abnormalities that delay esophageal emptying, such as esophageal stricture or atony
2) Patients with hypersensitivity to this drug or its components
3) Patients with hypocalcemia
4) Patients who cannot sit or stand upright for more than 30 minutes
5) Pregnant women, women who may be pregnant, and lactating women
6) Patients with severe renal impairment (creatinine clearance less than 30 mL/min)
7) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorbtion.

3. Administer with caution to the following patients.
1) Patients with upper gastrointestinal diseases such as Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers
2) This medicine contains Yellow No. 5 (Sunset Yellow FCF), so patients who are hypersensitive to this ingredient or have a history of allergy should administer it with caution.

4. Adverse reactions
1) The safety of administering 5 mg of this drug once daily in the treatment of postmenopausal osteoporosis was evaluated in four clinical trials involving 3,232 postmenopausal women aged 38 to 85. The trial period was 3 years, and there were 1,613 people in the drug-treated group and 1,619 in the placebo group. This clinical trial also included patients who already had digestive system disease and were taking non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors, or H2 antagonists. All women received 1,000 mg of calcium and up to 500 IU of vitamin D (if lower than normal levels).
(1) The mortality rate was 2.0% in the placebo group and 1.7% in the drug-administered group. The number of patients who developed serious adverse reactions was 24.6% in the placebo group and 27.2% in the drug-treated group. The rate of discontinuation of drug administration due to adverse reactions was 15.6% in the placebo group and 14.8% in the drug-administered group. Adverse reactions that occurred in more than 5% of patients in phase 3 clinical trials for the treatment of postmenopausal osteoporosis are as follows.

- Table (refer to attached document) -

(2) Laboratory findings: During the first 6 months, transient decreases in blood calcium (<1%) and phosphorus (<3%) concentrations were observed in patients receiving this medicine, accompanied by a compensatory increase in PTH (>30%). Over 3 years, there were no clear differences in blood calcium, phosphorus, or PTH concentrations between the treatment and placebo groups. Blood calcium concentrations of 8 mg/dL or less occurred in 18 patients: 9 patients (0.5%) in each group. Blood phosphorus concentrations of 2 mg/dL or less occurred in 14 patients: 11 (0.6%) in the treatment group and 3 (0.2%) in the placebo group. Abnormal liver function test results were reported rarely (<0.1%).
(3) Endoscopic examination was performed on patients complaining of moderate or severe gastrointestinal disease, and the same number of people in the group receiving this drug and the placebo group (75 patients each, 14.5% in the placebo group, 11.9% in the group receiving this drug). In this group of symptomatic patients, the number of patients presenting with clinically significant symptoms (perforation, ulceration, bleeding) was similar between the two groups (51% in the control group and 39% in the drug-treated group).
2) In the treatment of postmenopausal osteoporosis, the safety of administering 35 mg of this drug once a week was compared with the administration of 5 mg of this drug once a day in postmenopausal women aged 50 to 95 years. The trial period was 1 year, and there were 480 people in the group administered 5 mg of this drug once a day and 485 people in the group administered 35 mg of this drug once a week. This clinical trial also included patients who already had digestive system diseases and were taking NSAIDs, proton pump inhibitors, and H2 antagonists. All women received 1000 mg of calcium and up to 500 IU of vitamin D (if lower than normal levels).
(1) The mortality rate was 0.4% in the group administered 5 mg once a day and 1.0% in the group administered 35 mg once a week. The number of patients who developed severe adverse reactions was 7.1% in the 5 mg once daily group and 8.2% in the once weekly 35 mg group. The rate of drug discontinuation due to adverse reactions was 11.9% in the 5 mg once daily group and 11.5% in the once weekly 35 mg group. Overall safety and tolerability were similar in both groups.
(2) Digestive system: The incidence was similar in the 5 mg once daily group and the 35 mg once weekly group (indigestion 6.9%, 7.6%; diarrhea 6.3%, 4.9%; abdominal pain 7.3%, 7.6%, respectively).
(3) Musculoskeletal system: Joint pain was reported in 11.5% of the group administered 5 mg once a day, 14.2% of the group administered 35 mg once a week, and muscle pain was reported by 4.6% and 6.2%, respectively.
(4) Clinical test values: The average changes after 12 months of administration in the 5 mg once daily and 35 mg once weekly groups were similar (serum calcium 0.4%, 0.7%; serum phosphorus -3.8%, -2.6%; serum PTH 6.4%, 4.2%, respectively).
3) In the treatment of postmenopausal osteoporosis, the safety of administering 75 mg of this drug twice a month for two consecutive days was studied in postmenopausal women aged 50 to 86 years. The trial period was 2 years, and there were 613 people in the group administered 5 mg of this drug once a day and 616 people in the group administered 75 mg of this drug twice a month for two consecutive days. This clinical trial also included patients who already had digestive system diseases and were taking NSAIDs, proton pump inhibitors, and H2 antagonists. All women received 1000 mg of calcium and 400 to 800 IU of vitamin D.
(1) The mortality rate was 1.0% in the group administered 5 mg once a day and 0.5% in the group administered 75 mg twice a month for two consecutive days. The number of patients who developed severe adverse reactions was 10.8% in the group administered 5 mg once a day, and 14.4% in the group administered 75 mg twice a month for two consecutive days. The rate of discontinuation of drug administration due to adverse reactions was 14.2% in the group administered 5 mg once a day and 13.0% in the group administered 75 mg twice a month for two consecutive days. Overall safety and tolerability were similar in both groups.
(2) Acute phase reaction: 3.6% occurred in the group administered 5 mg once a day, and 7.6% occurred in the group administered 75 mg twice a month for two consecutive days. Acute phase reaction-like symptoms, in which fever or influenza-like symptoms appeared within the first 5 days of drug administration and lasted less than 7 days, were reported in 0.6% of the group administered 75 mg twice a month for two consecutive days and in 0.0% of the group administered 5 mg once a day.
(3) Digestive system: The incidence of drug discontinuation due to vomiting (0.2% and 1.0%, respectively) and diarrhea (0.3% and 1.0%, respectively) was higher in the group administered 75 mg twice a month for two consecutive days than in the group administered 5 mg once a day. Most of these reactions occurred within a few days after administration.
(4) Eyes: No patients experienced eye inflammation such as uveitis, scleritis, or iritis in the group administered 75 mg for two consecutive days twice a month, but uveitis occurred in one patient at 5 mg once a day.
(5) Clinical test values: In the group administered 5 mg once a day and the group administered 75 mg twice a month for two consecutive days, the average change after 24 months of administration was 0.2% and 0.8% in serum calcium; Serum phosphorus -1.9%, -1.3%; Serum PTH -10.4%, -17.2%).
4) The safety of administering 150 mg of this drug once a month in the treatment of postmenopausal osteoporosis was studied in postmenopausal women aged 50 to 88 years. The trial period was 1 year, and there were 642 people in the group administered 5 mg of this drug once a day and 650 people in the group administered 150 mg of this drug once a month. This clinical trial also included patients who already had digestive system diseases and were taking NSAIDs, proton pump inhibitors, and H2 antagonists. All women received 1,000 mg of calcium and up to 1,000 IU of vitamin D.
(1) The mortality rate was 0.5% in the group administered 5 mg once a day and 0.0% in the group administered 150 mg once a month. The number of patients who developed severe adverse reactions was 4.2% in the group administered 5 mg once a day and 6.2% in the group administered 150 mg once a month. The rate of discontinuation of drug administration due to adverse reactions was 9.5% in the 5 mg once daily group and 8.6% in the 150 mg once monthly group. Overall safety and tolerability were similar in both groups.
(2) Acute phase reaction: occurred in 1.1% of the group administered 5 mg once a day and 5.2% in the group administered 150 mg once a month. Acute phase reaction symptoms, in which fever or influenza-like symptoms appeared within the first 3 days of drug administration and lasted less than 7 days, were reported in 1.4% of the 150 mg once a month group and 0.2% of the once daily 5 mg group.
(3) Digestive system: The proportion of patients with diarrhea was higher in the 150 mg once a month group than in the 5 mg once daily group (4.7% and 8.2%, respectively). The rate of medication discontinuation due to epigastric pain (2.5% and 1.4%, respectively) and diarrhea (0.8% and 0.0%, respectively) in the group administered 150 mg once a month was slightly higher than that in the group administered 5 mg once daily, and most of these adverse reactions in the digestive system occurred within the first few days of administration. Medication discontinuation due to vomiting symptoms occurred at the same level in both groups (0.3% and 0.3%, respectively).
(4) Eyes: In the group administered 150 mg once a month, no patients experienced eye inflammation such as uveitis, scleritis, or iritis, but in the group administered 5 mg once a day, two patients developed iritis.
(5) Clinical test values: As a result of laboratory tests, in the group administered 150 mg once a month and the group administered 5 mg once a day, after 12 months, blood calcium increased by 0.3% and 0.1%, respectively, phosphate decreased by 2.3%, and PTH increased by 4.8% and 8.3%, respectively. In addition, after the first month of administration, the incidence of hypocalcemia was slightly higher in the group administered 150 mg once a month than the group administered 5 mg once daily (2.2% and 0.2%, respectively), but the subsequent incidence of hypocalcemia was similar in both groups (approximately 2%).
5) Osteoporosis in men
The overall safety and efficacy were similar to adverse reactions reported in osteoporosis clinical trials in postmenopausal women. Additionally, benign prostatic hyperplasia (5% in the risedronate sodium 35 mg group and 3% in the placebo group), nephrolithiasis (3% and 0%, respectively), and arrhythmia (2% and 0%, respectively).
6) Foreign post-marketing surveillance
Severe skin reactions including mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), hypersensitivity reactions including angioedema, rash, and blisters, and skin reactions have been reported very rarely. Upper gastrointestinal abnormalities such as esophagitis, esophageal ulcer, and gastric ulcer have been reported. In the musculoskeletal system, bone pain, arthralgia, and muscle pain were rarely reported, and external auditory canal osteonecrosis was reported very rarely (bisphosphonate-based adverse reaction). Eye inflammation, including iritis and uveitis, and jaw necrosis have been reported very rarely. Liver dysfunction and jaundice accompanied by marked elevations of AST, ALT, and γ-GTP have been reported (frequency unknown).
7) Domestic post-marketing survey
As a result of a post-marketing use outcome survey conducted on 933 people over 6 years in Korea, the occurrence rate of adverse reactions was reported to be 18.86% (176/933 people, 320 cases) regardless of causal relationship. Among these, adverse drug reactions for which a causal relationship with this drug cannot be ruled out were 6.65% (62 people/933 people, 85 cases), including indigestion (1.71%). % (16 people/933 people, 17 cases), anorexia 0.64% (6 people/933 people, 6 cases), nausea 0.64% (6 people/933 people, 6 cases), muscle pain 0.54% (5 people/933 people, 5 cases), abdominal pain 0.43% (4 people/933 people, 4 cases), asthenia 0.43% % (4 people/933 people, 4 cases), heartburn 0.32% (3 people/933 people, 3 cases), and pain in the solar plexus 0.32% (3 people/933 people, 4 cases). Unexpected adverse drug reactions were 1.29% (12 people/933 people, 15 cases), including anorexia at 0.64% (6 people/933 people, 6 cases), chest discomfort, palpitations, increased sweating, facial flushing, burning, kidney stones, belching, hematuria, and fever at 0.11% (1 person/933 people, 1 case).
8) As a result of analyzing domestic voluntary adverse event reporting data (1989-June 2014), the following adverse events were reported in statistically significantly higher numbers compared to adverse events occurring in other drugs for which adverse events were reported. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
⦁ Ophthalmology: Eye pain

5. General precautions
1) Bisphosphonate drugs are associated with esophagitis and esophageal ulcer formation. Therefore, patients should pay attention to the above dosage. Additionally, doctors and pharmacists should emphasize the importance of dosage for patients with a history of esophageal disease.
2) Hypocalcemia and other bone and mineral metabolism disorders (e.g., parathyroid dysfunction, vitamin D deficiency) must be treated before administering this drug. It is important for all patients to consume adequate amounts of calcium and vitamin D.
3) Localized jaw bone necrosis has been rarely reported when administering oral bisphosphonate agents. These symptoms were generally associated with local infection (including osteomyelitis) resulting in tooth extraction and/or delayed treatment (see Adverse Reactions section). Most of the cases of jaw necrosis reported to be related to bisphosphonate preparations occurred when intravenous bisphosphonate preparations were administered to cancer patients, but some also occurred in postmenopausal osteoporosis patients. Cancer, concomitant medications (e.g., chemotherapy, radiotherapy, corticosteroids), poor oral hygiene, concomitant diseases (e.g., periodontal disease and/or pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures), and smoking are known risk factors for jaw osteonecrosis. Patients who develop jaw bone necrosis should receive appropriate treatment from an oral surgeon. Dental surgery can make the situation worse. In patients requiring invasive dental procedures (e.g., tooth extraction, dental implants), discontinuation of bisphosphonate therapy may reduce the risk of jaw osteonecrosis. A management plan for each patient should be established based on individual benefit/risk assessment based on the clinical judgment of the treating physician.
4) Atypical, low-energy, or low-trauma fractures of the femoral shaft have been reported in patients treated with bisphosphonates. These fractures can occur anywhere on the femoral stem, from the lesser trochanter to just above the supracondylar flare, and are essentially horizontal or short oblique in the absence of evidence of comminution. Because these fractures also occur in patients with osteoporosis who have not received bisphosphonate treatment, a causal relationship has not been established.
Atypical femur fractures most commonly occur after minimal or no trauma. This can occur on both sides, and the majority of patients report general pain, usually dull, aching thigh pain, in the affected area for weeks to months before a complete fracture occurs. A few reports mention the concurrent use of glucocorticoid treatment (e.g., prednisone) when fractures occur.
Any patient presenting with thigh or groin pain who has a history of exposure to bisphosphonates should be suspected of having an atypical fracture and evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be evaluated for signs and symptoms of fracture in the contralateral limb. Discontinuation of bisphosphonate therapy should be considered while awaiting individual benefit/risk assessment.
5) Osteonecrosis of the external auditory canal was reported in patients who took bisphosphonates for a long period of time. Possible factors for external auditory canal osteonecrosis include local risk factors such as steroid use, chemotherapy, infection, or trauma. When administering bisphosphonates to patients with otic symptoms, including chronic otitis media, the possibility of external auditory canal osteonecrosis should be considered.
6) In post-marketing experience, severe and sometimes incapacitating bone, joint and/or muscle pain was rarely reported in patients receiving bisphosphonates. Bisphosphonate drugs also include this drug. Time to symptom onset varied from 1 day to several months after initiation of treatment. In most patients, symptoms were alleviated after discontinuation of treatment. In some of these patients, symptoms recurred when the same or a different bisphosphonate was readministered.
7) Information to be provided to patients
(1) Drugs, foods, and beverages other than pure water containing polyvalent cations (calcium, magnesium, iron, aluminum, etc.) should not be administered simultaneously because they may interfere with the absorption of this drug. Therefore, to obtain the proven benefits of this drug, this drug should be administered at least 30 minutes before the first food intake of the day or at least 2 hours after food intake.
(2) In order to allow the drug to reach the stomach quickly and reduce the possibility of esophageal irritation, the patient must swallow this drug with a sufficient amount of water (170 to 230 mL) and should not lie down for at least 30 minutes after taking it and until after the first food intake of the day.
(3) This medicine should not be chewed or sucked due to the possibility of ulceration of the oropharynx. Patients should especially avoid taking this medication before going to bed or waking up. Patients must be informed that the risk of esophageal disorders increases if these precautions are not followed. If symptoms of esophageal disease appear (difficulty or pain in swallowing food, pain behind the sternum, heartburn occurs or worsens), the patient must be instructed to stop taking this medicine and consult a doctor.
(4) Doctors should consider administering calcium and vitamin D as adjuvant therapy when intake from food is insufficient. In particular, male and female patients receiving long-term systemic corticosteroid treatment should take appropriate amounts of calcium and vitamin D.
(5) Weight-bearing exercise should be considered along with changes in specific habit factors such as excessive smoking and drinking.
(6) Doctors must instruct patients to read the product instructions before treating this drug and to read it again each time a new prescription is prescribed.

6. Interaction
1) Separate drug interaction studies have not been conducted on this drug. Among women participating in a phase 3 clinical trial for the treatment of postmenopausal osteoporosis, 31% took aspirin, 48% took NSAIDs, and 21% took H2 antagonists and/or proton pump inhibitors. The occurrence of upper gastrointestinal adverse reactions in patients who regularly took aspirin or NSAIDs for more than 3 days a week was similar in the test and control groups, and similar results were also observed in patients who took H2 antagonists and/or proton pump inhibitors.
2) If necessary, it can be used in combination with hormone replacement therapy.
3) Concurrent administration of calcium supplements, antacids, and oral medications containing polyvalent cations (calcium, magnesium, iron, aluminum, etc.) interferes with the absorption of this drug.
4) This drug is not metabolized systemically and does not induce or inhibit CYP-450 enzymes. The protein binding rate in human plasma is about 24%, and animal experiments showed that about 60% was distributed to bone. The remainder is excreted through the kidneys in an unmetabolized state.

7. Administration to pregnant and lactating women
1) Although there were no studies on pregnant women, it was reported in animal experiments that maternal hypocalcemia and fetal ossification effects may occur during the delivery period.
2) Considering the importance of this drug to nursing mothers, administration of this drug should be discontinued or breastfeeding should be discontinued.
3) In animal experiments, 1 to 26 times the human dose (30 mg/day) of this drug was administered to pregnant rats during the period formation period. During pregnancy, the number of live births decreased in rats administered oral doses approximately 5 times the human dose, and the body weight of newborns decreased in rats administered approximately 26 times the human dose. In rats administered approximately 2.5 times the human dose, the number of fetuses showing incomplete ossification of the sternal segment and skull clearly increased compared to the control group. In rats administered orally at approximately 5 times the human dose, both incomplete ossification and non-ossification of the sternal segment increased. Cleft palate was observed at a low incidence in rats administered orally at approximately the same dose as the human dose. The relevance of this drug to human use is uncertain.
When administered to rabbits at doses up to 10 mg/kg/day during pregnancy, no significant fetal ossification effect occurred. However, at 10 mg/kg/day, 1 of 14 pups was miscarried and 1 was born prematurely.
Similar to other bisphosphonate preparations, when administered to rats at 3.2 mg/kg/day (1 times the human dose) during mating and pregnancy, maternal peripartum hypocalcemia and death were observed.
This drug is detected in lactating rats within 24 hours after drug administration and is secreted through milk.

8 Administration to children
Safety and efficacy in children under 18 years of age have not been established.

9. Administration to elderly people
There is no difference in safety and efficacy between elderly and young patients.

10. Treatment in case of overdose
1) A decrease in blood calcium and phosphorus may be expected in some patients due to significant overdose. These patients may develop signs and symptoms of hypocalcemia. To reduce the absorption of this drug, milk or an antacid containing calcium should be administered.
2) In case of significant overdose, gastric lavage may be considered to remove unabsorbed drug. Standardized methods that are effective in treating hypocalcemia restore physiological amounts of ionized calcium and reduce the signs and symptoms of hypocalcemia.

11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
1 tablet/PTP

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Bonseron Tab. 150mgBonseron Tablet 150 mg (Precautions for use)2017.07.05HWPPrecautions for use of Bonseron tablets, Bonseron tablets 150mg.hwp
1Bonseron Tab. 150mgBonseron Tablet 150 mg (Precautions for use)2015.10.29HWPPermission change order (draft)_Precautions for use (risedronic acid)